Moderna· @moderna_tx · X·· 2026-06-02精选AI 评分62
AI 导读
Moderna与默沙东在2026年美国临床肿瘤学会（ASCO）年会上公布了intismeran autogene联合KEYTRUDA（帕博利珠单抗）治疗高危黑色素瘤患者的5年随访数据。Moderna官网发布了CEO Stéphane Bancel与首席开发官David Berman解读该结果的IR Insights视频。
推荐理由
Moderna与默沙东公布个体化新抗原疗法联合KEYTRUDA在高危黑色素瘤的5年随访数据，可了解该联合方案的长随访表现。
正文
Earlier today, Moderna and Merck presented 5-year follow-up data for intismeran autogene in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel and Chief Development Officer David Berman about these results. https://www.modernatx.com/recapping-moderna-asco-oral-presentation
#ASCO2026 #ASCO26
来源：Moderna · x.com